# An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis

> **NCT06613490** · EARLY_PHASE1 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 24 (estimated)

## Conditions studied

- Antisynthetase Syndrome
- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** anti CD19 CAR NK cells

## Key facts

- **NCT ID:** NCT06613490
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-20
- **Primary completion:** 2025-10-20
- **Final completion:** 2026-10-20
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06613490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06613490, "An Exploratory Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Antisynthetase Antibody Syndrome and Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06613490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*